Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. - Choueiri TK; Powles T; Albiges L; Burotto M; Szczylik C; Zurawski B; Yanez Ruiz E; Maruzzo M; Suarez Zaizar A; Fein LE; Schutz FA; Heng DYC; et al. (The New England journal of medicine, 2023)